GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Immunovia AB (OSTO:IMMNOV) » Definitions » Short Interest

Immunovia AB (OSTO:IMMNOV) Short Interest


View and export this data going back to 2015. Start your Free Trial

What is Immunovia AB Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Immunovia AB's Short Interest

For the Diagnostics & Research subindustry, Immunovia AB's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunovia AB's Short Interest Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Immunovia AB's Short Interest distribution charts can be found below:

* The bar in red indicates where Immunovia AB's Short Interest falls into.


Immunovia AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Immunovia AB (OSTO:IMMNOV) » Definitions » Short Interest
Comparable Companies
XSAT:SPERM XSAT:GEAN OSTO:PROGEN XSAT:ALPH XSAT:CALMA B NGM:ATANA OSTO:AROC TMO DHR SHSE:603259 IDXX IQV A XSWX:LONN MTD ICLR ILMN LH DGX WAT
Traded in Other Exchanges
0G8X:UK
Address
Medicon Village, Scheelevagen 8, Lund, SWE, 223 63
Website
https://www.immunovia.com
Immunovia AB molecular diagnostic company. It develops and commercializes diagnostic tools for complex forms of cancer and autoimmune diseases. Its technology platform IMMray (TM), is based on antibody microarray analysis. The company is currently developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer.

Immunovia AB Headlines

No Headlines